• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

    9/25/25 8:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email

    --Combined Funding Strengthens Bay Area Community with STEM Curriculum, Building Scientific, Technology and Mathematics Literacy--

    Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond. The funding, distributed through the Gilead Foundation, will build on the company's ongoing work to cultivate a robust talent pipeline comprised of students from a broad spectrum of backgrounds and experiences. These donations represent an ongoing commitment to supporting organizations where Gilead colleagues live and work, including a $1 million grant to the Boys and Girls Clubs of America and $500,000 to the San Mateo Foster City Education Foundation to build STEM curriculum.

    With STEM skills projected to be essential for 80% of all jobs by the end of the decade, the Gilead Foundation's investment is a powerful step toward closing the opportunity gap and preparing students for the future. The U.S. faces a projected shortfall of 1.4 million skilled STEM workers by 2030, making access to STEM education more urgent than ever.

    "The Gilead Foundation's commitments will help promote promising futures for students in the Bay Area and beyond with the goal of strengthening our local communities," said Keeley Wettan, Senior Vice President, Legal at Gilead and Gilead Foundation Board Member. "STEM skills have become a necessity for the modern workforce across the country, but many students need better access to the educational experiences needed to grow these skills. We're proud to partner with organizations that are on the front line of this work."

    The Gilead Foundation's grants will support organizations working to strengthen STEM learning opportunities for students from elementary school through college. Recent commitments include:

    • A $1 million grant to the Boys and Girls Clubs of America to support STEM programs for elementary through high school students in eight sites across the Bay Area, Los Angeles, Maryland, Washington D.C., New Jersey and North Carolina.
    • A $500,000 grant to the San Mateo Foster City Education Foundation to support STEM education for elementary and middle school students in the San Mateo-Foster City School District.
    • $5 million in grants to San Francisco State University to support the construction of their new Science and Engineering Innovation Center (SEIC) and student programming.

    "High-quality STEM education is critical for building a skilled workforce, but too many students lack access to these opportunities," said Lisa Anastasi, Executive Vice President and Chief Development and External Relations Officer at Boys & Girls Clubs of America. "We must work to close the skills gap and empower every young person to explore the possibilities of STEM, including potential career paths. We're proud to partner with the Gilead Foundation to help build a STEM workforce that reflects the talent and potential in all our communities."

    "Every student deserves access to STEM experiences, regardless of their background or zip code," said Diego Ochoa, Superintendent of the San Mateo-Foster City School District. "STEM education not only builds scientific, technological and mathematical literacy, but also cultivates seminal problem-solving skills and critical thinking in our students. When these opportunities aren't accessible to all, we lose out on incredible potential. It's time to change the narrative and the reality: all kids deserve the opportunity to be in STEM."

    These recent investments follow the official launch of San Francisco State University's SEIC facility, which opened its doors earlier this year, serving a predominantly local student population drawn from Bay Area communities. The Gilead Foundation's grant provided state of the art research equipment and resources to support students' pursuit of STEM degrees - and careers - across biopharma, biotech and engineering.

    "We're so grateful for the Gilead Foundation's generous investment in San Francisco State University," said Carmen Domingo, Dean of the College of Science and Engineering at SFSU. "Our students will be the next generation of scientists, engineers and healthcare professionals pushing us forward, and it's crucial that they are given the opportunity to be trained on modern technologies and with tools that are most in demand. The resources housed in the new Science and Engineering Innovation Center will greatly increase our ability to prepare students to thrive across careers in STEM in our communities."

    The Gilead Foundation's investments build on the company's longstanding commitment toward supporting organizations in the Bay Area, including those building the next-generation STEM workforce. Since 2018, Gilead has awarded more than $150 million in grant funding to nearly 250 nonprofit organizations in the region working to advance education equity and strengthen a diverse workforce pipeline.

    About the Gilead Foundation

    The Gilead Foundation is a nonprofit organization that works to create a thriving health ecosystem. The Gilead Foundation takes a holistic approach to mitigate the root causes of health inequities by providing resources to organizations that empower people with the skills to be their own best advocate and create systems of support that strengthen communities, classrooms and workplaces.

    About Gilead Sciences

    Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

    # # #

    Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

    For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250925022835/en/

    Jessica Smith, Media

    [email protected]

    Jacquie Ross, Investors

    [email protected]

    Get the next $GILD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GILD

    DatePrice TargetRatingAnalyst
    2/11/2026$140.00 → $170.00Buy
    Needham
    1/7/2026$145.00Buy
    UBS
    11/24/2025$140.00Buy
    Truist
    11/13/2025$140.00Sector Outperform
    Scotiabank
    8/19/2025$128.00Neutral → Outperform
    Daiwa Securities
    8/8/2025$127.00Hold → Buy
    Truist
    7/25/2025$133.00Hold → Buy
    Needham
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Gilead Sciences with a new price target

    Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously

    2/11/26 7:05:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Gilead Sciences with a new price target

    UBS resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $145.00

    1/7/26 9:10:38 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on Gilead Sciences with a new price target

    Truist resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $140.00

    11/24/25 8:41:38 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    SEC Filings

    View All

    Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

    2/10/26 4:02:13 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Gilead Sciences Inc.

    SCHEDULE 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/5/26 1:23:14 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Gilead Sciences Inc.

    144 - GILEAD SCIENCES, INC. (0000882095) (Subject)

    11/28/25 1:02:54 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

    2/13/24 5:48:49 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO O'Day Daniel Patrick exercised 115,640 shares at a strike of $66.01 and sold $17,346,000 worth of shares (115,640 units at $150.00) (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/6/26 4:22:37 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Comm & Corp Aff Officer Mercier Johanna was granted 44,867 shares and covered exercise/tax liability with 24,800 shares, increasing direct ownership by 19% to 123,288 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/5/26 6:51:29 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Dickinson Andrew D was granted 44,867 shares and covered exercise/tax liability with 24,802 shares, increasing direct ownership by 13% to 170,568 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/5/26 6:49:59 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

    2/10/26 4:02:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

    Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $14.3 billion for Full Year 2025 Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2025. "Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "In 2026, our potential new launches include two cancer therapies and an additional HIV

    2/10/26 4:01:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

    – Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – Kite, a Gilead Company (NASDAQ:GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell therapy approved for R/R large B-cell lymphoma to have this Limitations of Use removed.

    2/6/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Leadership Updates

    Live Leadership Updates

    View All

    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par

    12/18/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $GILD
    Financials

    Live finance-specific insights

    View All

    Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

    2/10/26 4:02:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

    Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $14.3 billion for Full Year 2025 Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2025. "Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "In 2026, our potential new launches include two cancer therapies and an additional HIV

    2/10/26 4:01:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a health

    1/27/26 4:05:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/9/24 6:21:28 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 3:32:27 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Gilead Sciences Inc.

    SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 2:49:26 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care